Literature DB >> 1384014

Regulation of prostatic carcinoma cell proliferation and secretory activity by extracellular matrix and stromal secretions.

C J Fong1, E R Sherwood, E J Braun, L A Berg, C Lee, J M Kozlowski.   

Abstract

Previous studies from our laboratory have shown that reconstituted basement membrane and stromal secretory products are important regulators of benign prostatic epithelial cell growth and differentiation. In the present study we evaluated the impact of extracellular matrix (ECM) and soluble stromal secretory products on the proliferation and secretory activity of the androgen-responsive prostatic carcinoma cell line LNCaP. In these studies, dihydrotestosterone (DHT) was a potent mitogen for LNCaP cells cultured on plastic or on type I collagen. The growth response to DHT was greatly attenuated when LNCaP cells were grown on prostatic stromal ECM. Cells grown on stromal ECM also exhibited clustered morphology compared to the monolayer growth observed on plastic and secreted elevated levels of prostate specific antigen (PSA) and prostatic acid phosphatase (PAP). These findings indicate that cultivation of LNCaP on stromal ECM will promote the expression of differentiated functions. In additional studies, stromal cell conditioned medium (SCM) significantly increased PSA/PAP secretion by LNCaP cells in the presence of 10 nM DHT. The enhancement of DHT-induced PSA/PAP secretion by SCM was most pronounced when LNCaP cells were grown on stromal ECM. SCM did not significantly alter LNCaP proliferation. These studies indicate that prostatic stromal ECM and soluble secretory products will promote differentiated function in cultured LNCaP cells. In addition, we show that DHT can act as either a growth or differentiation-promoting stimulus depending on the presence of stromal factors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1384014     DOI: 10.1002/pros.2990210205

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  7 in total

1.  COUP-TF upregulates NGFI-A gene expression through an Sp1 binding site.

Authors:  C Pipaón; S Y Tsai; M J Tsai
Journal:  Mol Cell Biol       Date:  1999-04       Impact factor: 4.272

Review 2.  Three-dimensional cultures of prostatic cells: tissue models for the development of novel anti-cancer therapies.

Authors:  K C O'Connor
Journal:  Pharm Res       Date:  1999-04       Impact factor: 4.200

3.  The CXCL12/CXCR4 axis promotes ligand-independent activation of the androgen receptor.

Authors:  Sathish Kasina; Jill A Macoska
Journal:  Mol Cell Endocrinol       Date:  2012-01-08       Impact factor: 4.102

4.  Overview of samarium sm 153 lexidronam in the treatment of painful metastatic bone disease.

Authors:  Oliver Sartor
Journal:  Rev Urol       Date:  2004

5.  Changes in prostate-specific antigen (PSA) level correlate with growth inhibition of prostate cancer cells treated in vitro with a novel anticancer drug, irofulven.

Authors:  A L Woynarowska BAHigdon; R M Muñoz; P Bushong; S J Waters
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

Review 6.  Epidermal growth factor-related peptides and the epidermal growth factor receptor in normal and malignant prostate.

Authors:  E R Sherwood; C Lee
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

7.  PC-3 prostate carcinoma cells release signal substances that influence the migratory activity of cells in the tumor's microenvironment.

Authors:  Melanie J Voss; Bernd Niggemann; Kurt S Zänker; Frank Entschladen
Journal:  Cell Commun Signal       Date:  2010-07-13       Impact factor: 5.712

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.